UroGen Pharma Ltd.URGNNASDAQ
LOADING
|||
EPS Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year earnings per share growth rate
Latest
34.29%
↑ 144% above average
Average (39q)
-77.47%
Historical baseline
Range
High:276.12%
Low:-3145.61%
Volatility
-4417.1%
Relatively stable
| Period | Value |
|---|---|
| Q3 2025 | 34.29% |
| Q2 2025 | -14.13% |
| Q1 2025 | -15.00% |
| Q4 2024 | -45.45% |
| Q3 2024 | 39.56% |
| Q2 2024 | 6.19% |
| Q1 2024 | -34.72% |
| Q4 2023 | -5.88% |
| Q3 2023 | 33.98% |
| Q2 2023 | 20.77% |
| Q1 2023 | -6.56% |
| Q4 2022 | -7.96% |
| Q3 2022 | 4.24% |
| Q2 2022 | 5.60% |
| Q1 2022 | 1.57% |
| Q4 2021 | 5.93% |
| Q3 2021 | -15.38% |
| Q2 2021 | 0.00% |
| Q1 2021 | 15.22% |
| Q4 2020 | -5.34% |
| Q3 2020 | 9.03% |
| Q2 2020 | 19.55% |
| Q1 2020 | 3.76% |
| Q4 2019 | -75.47% |
| Q3 2019 | 1.85% |
| Q2 2019 | 2.70% |
| Q1 2019 | 23.97% |
| Q4 2018 | -14.06% |
| Q3 2018 | -12.28% |
| Q2 2018 | -29.55% |
| Q1 2018 | -18.92% |
| Q4 2017 | -3145.61% |
| Q3 2017 | 96.60% |
| Q2 2017 | -116.13% |
| Q1 2017 | -126.27% |
| Q4 2016 | 276.12% |
| Q3 2016 | -139.29% |
| Q2 2016 | 84.53% |
| Q1 2016 | 43.96% |
| Q4 2015 | 0.00% |